FDA approval of immunotherapy for rectal cancer after a trial involving 154 patients

The US Food and Drug Administration has approved an immunotherapy drug for a specific type of rectal cancer. In the clinical trial, which included 154 patients, nearly three-quarters did not need surgery, radiation, or chemotherapy. According to reports, the approval is an important development for patients with this type of cancer.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The trial included 154 patients with a specific type of rectal cancer.

  «in a clinical trial of 154 patients with one specific kind of rectal cancer»

  Morning Overview on MSN
• It was found that nearly three-quarters of the patients did not need surgery.

  «left almost three-fourths of them with no need for surgery»

  Morning Overview on MSN
• Swim Across America, an organization, funded the research that led to the approval.

  «Swim Across America-funded cancer research leads to landmark FDA approval»

  EurekAlert!

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms